Search results
Showing 781 to 795 of 2107 results for technology appraisal
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.
Show all sections
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
NICE's past research and projects
Information about medical technologies advisory committee registration and meetings
More detail about medical technologies advisory committee registration, meeting arrangements and types of attendee.
Information about medical technologies advisory committee registration and meetings
More detail about medical technologies advisory committee registration, meeting arrangements and types of attendee.
Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Nusinersen and risdiplam for treating spinal muscular atrophy (TA1162)
Evidence-based recommendations on nusinersen (Spinraza) and risdiplam (Evrysdi) for treating spinal muscular atrophy.
This guidance evaluates digital technologies, diagnostics and medical devices (including artificial intelligence).
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.
Tildrakizumab for treating active psoriatic arthritis [ID6724]
Awaiting development Reference number: GID-TA11807 Expected publication date: TBC
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.